| First Author | Yao Y | Year | 2013 |
| Journal | Eur J Immunol | Volume | 43 |
| Issue | 1 | Pages | 125-36 |
| PubMed ID | 23002042 | Mgi Jnum | J:191109 |
| Mgi Id | MGI:5460959 | Doi | 10.1002/eji.201242758 |
| Citation | Yao Y, et al. (2013) Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8(+) regulatory cells. Eur J Immunol 43(1):125-36 |
| abstractText | Inflammatory bowel diseases (IBDs) are complex multifactorial immunological disorders characterized by dysregulated immune reactivity in the intestine. Here, we investigated the contribution of Qa-1-restricted CD8(+) Treg cells in regulating experimental IBD in mice. We found that CD8(+) T cells induced by T-cell vaccination ameliorated the pathological manifestations of dextran sulfate sodium induced IBD when adoptively transferred into IBD mice. In addition, CD8(+) cell suppressive activity was induced by vaccination with glatiramer acetate (GA), an FDA-approved drug for multiple sclerosis (MS). We next showed that GA-induced CD8(+) Treg cells worked in a Qa-1-dependent manner and their suppressive activity depends on perforin-mediated cytotoxicity. Finally, we confirmed the role of CD4(+) T cells in dextran sulfate sodium induced colitis progression, and clarified that GA-induced CD8(+) T cells exerted their therapeutic effects on colitis by targeting pathogenic CD4(+) T cells. Our results reveal a new regulatory role of Qa-1-restricted CD8(+) Treg cells in IBD and suggest their induction by GA vaccination as a potential therapeutic approach to IBD. |
